NCT04751786 - Dose Escalation Study of Immunomodulatory Nanoparticles | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

January 11, 2021

Primary Completion Date

July 31, 2025

Study Completion Date

December 31, 2025

Conditions

Advanced Solid Tumor

Interventions

DRUG

PRECIOUS-01

Subjects will be enrolled in one of three dosing cohorts (three subjects per cohort for the planned dose escalation with a planned extension to a total of six subjects for the two highest dosing cohorts for the evaluation of the pharmacodynamic effects of PRECIOUS-01 for determination of the RP2D, if MTD is not reached).

Trial Locations (1)

6525 GA

Radboudumc, Nijmegen